TWI857935B - 水凝膠交聯化的玻尿酸前藥組合物及方法 - Google Patents

水凝膠交聯化的玻尿酸前藥組合物及方法 Download PDF

Info

Publication number
TWI857935B
TWI857935B TW107109913A TW107109913A TWI857935B TW I857935 B TWI857935 B TW I857935B TW 107109913 A TW107109913 A TW 107109913A TW 107109913 A TW107109913 A TW 107109913A TW I857935 B TWI857935 B TW I857935B
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
group
drug
Prior art date
Application number
TW107109913A
Other languages
English (en)
Chinese (zh)
Other versions
TW201842936A (zh
Inventor
賽巴斯蒂安 史塔克
湯瑪士 克納普
哈羅德 瑞
尼可拉 畢謝
博哈德 勞佛
托拜斯 佛吉特
傑曼尼 佛齊
派翠克 柯恩格
卿瑋 薇薇安 李
丹尼艾拉 邦巴卡 雅達弗
山謬 韋斯布羅德
Original Assignee
丹麥商阿仙帝斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商阿仙帝斯製藥公司 filed Critical 丹麥商阿仙帝斯製藥公司
Publication of TW201842936A publication Critical patent/TW201842936A/zh
Application granted granted Critical
Publication of TWI857935B publication Critical patent/TWI857935B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
TW107109913A 2017-03-22 2018-03-22 水凝膠交聯化的玻尿酸前藥組合物及方法 TWI857935B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762475094P 2017-03-22 2017-03-22
US62/475,094 2017-03-22

Publications (2)

Publication Number Publication Date
TW201842936A TW201842936A (zh) 2018-12-16
TWI857935B true TWI857935B (zh) 2024-10-11

Family

ID=61906882

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107109913A TWI857935B (zh) 2017-03-22 2018-03-22 水凝膠交聯化的玻尿酸前藥組合物及方法

Country Status (14)

Country Link
US (3) US11642415B2 (enExample)
EP (1) EP3600441A1 (enExample)
JP (2) JP7216006B2 (enExample)
KR (2) KR102715397B1 (enExample)
CN (1) CN110891611B (enExample)
AR (1) AR111190A1 (enExample)
AU (1) AU2018240375C1 (enExample)
CA (1) CA3055985A1 (enExample)
IL (1) IL269506B2 (enExample)
MA (1) MA49265A (enExample)
SG (2) SG11201908547VA (enExample)
TW (1) TWI857935B (enExample)
WO (1) WO2018175788A1 (enExample)
ZA (1) ZA201905930B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3055985A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
IL319735A (en) * 2018-09-26 2025-05-01 Ascendis Pharma As Degradable hyaluronic acid hydrogels
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
CN113316452A (zh) 2019-01-04 2021-08-27 阿森迪斯药物肿瘤股份有限公司 先天性免疫激动剂的持续局部药物水平
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
TWI856997B (zh) 2019-01-04 2024-10-01 丹麥商阿仙帝斯製藥公司 模式辨別受體(pattern recognition receptor)促效劑的共軛物
TW202114738A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254609A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020419444A1 (en) 2020-01-03 2022-06-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
JP2023540701A (ja) 2020-08-28 2023-09-26 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス グリコシル化ｉｌ－２タンパク質及びその使用
BR112023018802A2 (pt) 2021-04-01 2023-10-31 Ascendis Pharma As Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
WO2023001288A1 (zh) * 2021-07-23 2023-01-26 百奥泰生物制药股份有限公司 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
MX2024006698A (es) 2021-12-13 2024-06-19 Ascendis Pharma Oncology Div A/S Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8).
JP2025512364A (ja) * 2022-04-15 2025-04-17 バリター，インコーポレイティド 精製多価タンパク質－ヒアルロン酸ポリマーコンジュゲート
CN115389681B (zh) * 2022-11-01 2023-01-20 常州百瑞吉生物医药有限公司 一种巯基化透明质酸衍生物中二硫苏糖醇残留的检测方法
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
AU2024232125A1 (en) 2023-03-06 2025-08-28 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010626A (zh) * 2011-10-12 2014-08-27 阿森迪斯药物眼科部股份有限公司 眼病症的预防和治疗
CN104995303A (zh) * 2012-12-18 2015-10-21 诺华股份有限公司 利用结合乙酰透明质酸的肽标签的组合物和方法

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4716224A (en) 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
EP0326111A3 (en) 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
SE8900422D0 (sv) 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0797965B1 (en) 1990-06-14 2001-08-16 Vitaphore Corporation Wound dressing and catheter securing using a polyurethane-biopolymer composite
CA2086527A1 (en) 1990-07-26 1992-01-27 Samuel J. Tremont Polymeric drug delivery system
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993009176A2 (en) 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
GB9216925D0 (en) 1992-08-10 1992-09-23 Royal Holloway Microspheres of polyhydroxylic materials
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
US6063396A (en) 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5690961A (en) 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IT1281886B1 (it) 1995-05-22 1998-03-03 Fidia Advanced Biopolymers Srl Processo per la preparazione di idrogel ottenuti da derivati chimici dell'acido ialuronico mediante irradiazioni ultraviolette e loro
US5612321A (en) 1995-06-22 1997-03-18 Hercules Incorporated Antioxidant grafted polysaccharides
JP3130234B2 (ja) 1995-09-29 2001-01-31 デンセイ・ラムダ株式会社 インバータ装置
DE69739656D1 (de) 1996-02-09 2009-12-31 Amgen Inc 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
JP4247846B2 (ja) 1997-07-03 2009-04-02 デュピュイ・スパイン・インコーポレーテッド 架橋ポリサッカリド薬物キャリア
JPH1133104A (ja) 1997-07-16 1999-02-09 Res Inst For Prod Dev 生体組織への接着性を有する医用材料
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP1082963A4 (en) 1998-05-20 2004-03-17 Chugai Pharmaceutical Co Ltd MEDICINE FOR HYALURONIC ACID-ASSOCIATED JOINT DISEASES
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
JP2000119196A (ja) 1998-10-07 2000-04-25 Menicon Co Ltd 眼科用薬剤徐放材及びその製造方法
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
AU2707500A (en) 1998-12-04 2000-06-26 Incept Llc Biocompatible crosslinked polymers
WO2000054762A2 (en) 1999-03-15 2000-09-21 Trustees Of Boston University Use of cross linked polysaccharides for the inhibition of angiogenesis
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
AU2574701A (en) 1999-11-26 2001-06-12 Regents Of The University Of Michigan, The Reversible cross-linked hydrogels
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
PT1305057E (pt) 2000-07-31 2005-11-30 Iscience Corp Composicao de biomateria microparticular para uso medicinal
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
US7008633B2 (en) 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
WO2002068383A2 (en) 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Thiol-modified hyaluronan
ITMI20011238A1 (it) 2001-06-12 2002-12-12 Bartholdy Consultadoria E Serv Polimeri polisaccaridici di origine naturale coniugati chimicamente asostanze farmacologicamente o biologicamente attive e loro proprieta'
ITPD20020064A1 (it) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
EP1490083A1 (en) 2002-03-29 2004-12-29 The Regents of the University of California Microgel particles for the delivery of bioactive materials
WO2003084571A1 (en) 2002-04-08 2003-10-16 Denki Kagaku Kogyo Kabushiki Kaisha Therapeutic composition for bone infectious disease
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
KR100507545B1 (ko) 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
JP5156890B2 (ja) 2002-09-11 2013-03-06 独立行政法人物質・材料研究機構 高分子架橋体及びその製造方法
WO2004046200A1 (ja) 2002-11-21 2004-06-03 Chugai Seiyaku Kabushiki Kaisha 薬物徐放担体
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7776240B2 (en) 2003-01-17 2010-08-17 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
AU2003901834A0 (en) 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
EP1620076A4 (en) 2003-04-25 2010-08-25 Kos Life Sciences Inc HIGH SUPERPOREOUS HYDROGEL FORMATION
JP2004323454A (ja) 2003-04-25 2004-11-18 Chisso Corp 薬剤
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US8153591B2 (en) 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
US8124120B2 (en) 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
GB0411583D0 (en) 2004-05-24 2004-06-23 Univ Bath Process
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006113668A1 (en) 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN101217982B (zh) 2005-07-06 2012-10-10 生化学工业株式会社 药剂导入光交联透明质酸衍生物凝胶
US8679536B2 (en) 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
WO2007026362A2 (en) 2005-09-02 2007-03-08 Colbar Lifescience Ltd. Cross-linked polysaccharide and protein matrices and methods for their preparation
EP1934265A4 (en) 2005-09-15 2009-06-24 Univ Utah Res Found POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING SAME
WO2007035080A1 (en) 2005-09-21 2007-03-29 Universiteit Van Amsterdam Novel cross-linkers for obtaining structure information on molecule complexes
KR101554834B1 (ko) 2005-10-12 2015-09-21 세이가가쿠 고교 가부시키가이샤 점막에 적용하는 작용제 및 그것의 제조 방법
WO2007047997A2 (en) 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007070546A2 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects
US7879818B2 (en) 2005-12-23 2011-02-01 Janos Borbely Hyaluronic acid-based cross-linked nanoparticles
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
CA2649915A1 (en) 2006-04-20 2007-11-01 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
EP1942117A1 (en) 2006-12-29 2008-07-09 Sigea S.R.L. Derivatives of acid polysaccharides
KR20080073419A (ko) 2007-02-06 2008-08-11 주식회사 핸슨바이오텍 의료용 히알루론산 유도체 마이크로비드 및 이의 제조 방법
EP1992364A1 (en) 2007-05-16 2008-11-19 Biosuma S.r.l. Carboxylated polysaccharides phosphated or bisphosphonated derivatives, optionally cross-linked, and their preparation and biomedical uses
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
EP2090592A1 (en) 2007-07-31 2009-08-19 OctoPlus Sciences B.V. Biodegradable hydrogels based on click chemistry
KR101062320B1 (ko) 2007-08-01 2011-09-05 포항공과대학교 산학협력단 가교결합성 히알루론산 유도체 제조방법 및 그 히알루론산유도체의 가교결합물
MX2010001629A (es) 2007-08-10 2010-08-09 Alessandro Sannino Hidrogeles de polimero y metodos de preparacion de los mismos.
US20100210509A1 (en) 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
SG185279A1 (en) 2007-10-11 2012-11-29 Inst Nat Sante Rech Med Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery
WO2009047347A1 (en) 2007-10-11 2009-04-16 Inserm (Institut National De Sante Et De La Recherche Medicale) Method for preparing porous scaffold for tissue engineering
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US9109051B2 (en) 2007-12-19 2015-08-18 Evonik Goldschmidt Gmbh Crosslinked hyaluronic acid in emulsion
AU2008341180A1 (en) 2007-12-21 2009-07-02 Encecor Ab Cross-linked hydrogel containing an active substance
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
IE20080211A1 (en) 2008-03-20 2009-11-25 Nat Univ Ireland Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
CN101538377A (zh) 2008-03-20 2009-09-23 上海昊海生物科技有限公司 一种交联透明质酸凝胶及其制备方法
ES2656350T3 (es) 2008-03-28 2018-02-26 The Regents Of The University Of California Conjugados polipéptido-polímero y procedimientos de uso de los mismos
JP2011520983A (ja) 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
GB0816496D0 (en) 2008-09-10 2008-10-15 Zhao Xiaobin Hyaluronic acid cryogel
CN101721349B (zh) 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 可注射原位交联水凝胶及其制备方法和用途
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
ITRM20080636A1 (it) 2008-11-28 2010-05-29 Univ Palermo Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli.
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US11090387B2 (en) 2008-12-22 2021-08-17 The Trustees Of The University Of Pennsylvania Hydrolytically degradable polysaccharide hydrogels
FR2945949B1 (fr) 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
CN102458471A (zh) * 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
WO2010138074A1 (en) 2009-05-29 2010-12-02 Hilborn Joens Hyaluronic acid based delivery systems
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR101091028B1 (ko) 2009-07-02 2011-12-09 아주대학교산학협력단 체내 주입형 하이드로젤 및 이의 생의학적 용도
EP2448604B1 (en) 2009-07-02 2016-03-23 Actamax Surgical Materials LLC Hydrogel tissue adhesive for medical use
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
KR101770844B1 (ko) 2009-07-31 2017-08-23 아센디스 파마 에이에스 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
SG178369A1 (en) 2009-08-11 2012-04-27 Agency Science Tech & Res Particulate hyaluronic acid formulations for cellular delivery of bioactive agents
JO3008B1 (ar) 2009-08-13 2016-09-05 Seikagaku Kogyo Co Ltd تركيب صيدلي لتخفيف الألم
KR101103423B1 (ko) 2009-09-04 2012-01-06 아주대학교산학협력단 생체 주입형 조직 접착성 하이드로젤 및 이의 생의학적 용도
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
AU2010334412B2 (en) 2009-12-22 2016-02-04 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
CA2791050A1 (en) 2010-03-01 2011-09-09 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of use thereof
RU2012145811A (ru) 2010-03-29 2014-05-10 Евоник Корпорейшн Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения
ES2527536T7 (es) 2010-04-27 2016-03-08 Synaffix B.V. Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
WO2011148116A2 (fr) 2010-05-27 2011-12-01 Laboratoire Idenov Acide hyaluronique modifie, procede de fabrication et utilisations
WO2011163069A2 (en) 2010-06-21 2011-12-29 The Trustees Of The University Of Pennsylvania Protease triggered release of molecules from hydrogels
US9315772B2 (en) 2010-06-22 2016-04-19 Universite De Rouen Crosslinked hyaluronan hydrogels for 3D cell culture
IT1401498B1 (it) 2010-07-30 2013-07-26 Mero Srl Idrogelo a base di acido ialuronico e suo uso in ortopedia
EP2629809B1 (en) 2010-10-20 2016-12-07 Allergan Holdings France S.A.S. Threads of cross-linked hyaluronic acid and methods of preparation and use thereof
FR2967677B1 (fr) 2010-11-18 2014-05-16 Centre Nat Rech Scient Derives de polysaccharides comprenant un motif alcene et reaction de couplage par chimie thio-clic
US20140038826A1 (en) 2011-01-28 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Covalently cross linked hydrogels and methods of making and using same
SI2682409T1 (sl) 2011-03-03 2017-08-31 Chugai Seiyaku Kabushiki Kaisha Derivat hialuronske kisline modificiran z amino-karboksilno kislino
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
JPWO2012165462A1 (ja) 2011-05-31 2015-02-23 国立大学法人 東京大学 ハイドロゲル及びその製造方法
ES2738208T3 (es) 2011-06-03 2020-01-20 Allergan Ind Sas Composiciones de relleno dérmico que incluyen antioxidantes
CN102226009B (zh) 2011-06-09 2013-04-10 西安力邦制药有限公司 一种交联透明质酸凝胶的制备方法
US9592251B2 (en) 2011-06-16 2017-03-14 The Hong Kong University Of Science And Technology Multi-vinylsulfone containing molecule
HK1198913A1 (en) 2011-08-12 2015-06-19 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US9044515B2 (en) 2011-09-06 2015-06-02 University Of Delaware Chemical conjugates for targeted degradation under reducing conditions
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2848142C (en) 2011-09-07 2021-05-18 Prolynx Llc Hydrogels with biodegradable crosslinking
EP2753607B1 (en) 2011-09-09 2016-04-13 Berry And Associates, Inc. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
EP3243533B1 (en) 2011-10-11 2020-06-17 Allergan Holdings France S.A.S. Threads of cross-linked hyaluronic acid and methods of use thereof
WO2013071216A1 (en) 2011-11-11 2013-05-16 Miba Medical Inc. Injectable filler
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
HK1205697A1 (zh) 2012-04-25 2015-12-24 Ascendis Pharma A/S 含有羟基的药物的前药
KR101374271B1 (ko) 2012-05-02 2014-03-14 주식회사 제네웰 히알루론산 에폭사이드 가교체 및 그 제조방법
JP6343604B2 (ja) 2012-05-18 2018-06-13 メディカル リサーチ カウンシル ＢＣＮ基を含むアミノ酸をコードする直交性コドンと、直交性ＰｙｌＲＳ合成酵素とを使用して、ＢＣＮ基を含むアミノ酸をポリペプチドに取り込む方法
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CZ304512B6 (cs) 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
KR101445265B1 (ko) 2012-09-18 2014-09-30 포항공과대학교 산학협력단 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물
US9644076B2 (en) 2012-09-25 2017-05-09 Max-Planck-Gesellschaft zur Foerderung der Wissenschafen e. V. Cross-linkers for hydrogels, hydrogels including these cross-linkers and applications thereof
MX370543B (es) 2012-10-11 2019-12-17 Ascendis Pharma Ophthalmology Div A/S Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
CN102942699B (zh) 2012-10-26 2014-07-02 暨南大学 一种自增强双交联透明质酸水凝胶及其制备方法
CN102911380B (zh) 2012-10-29 2015-03-18 北京爱美客生物科技有限公司 透明质酸与生物可降解高分子改性材料及制备方法
US9220807B2 (en) 2012-11-04 2015-12-29 Miba Medical Inc. Non-toxic cross-linker for hyaluronic acid
EP2727597A1 (en) 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha)
ITPD20120360A1 (it) 2012-11-30 2014-05-31 Fidia Farmaceutici "nuovi geli viscoelastici in chirurgia oftalmica"
WO2014096257A1 (en) 2012-12-19 2014-06-26 Novozymes Biopharma Dk A/S Freeze-dried cross-linked hyaluronic acid sponge
US9498539B2 (en) 2012-12-27 2016-11-22 Molly Sandra Shoichet Affinity-based controlled release system
CN105007896B (zh) 2012-12-28 2019-04-09 雅培心血管系统公司 包含抗体的治疗组合物
EP2958947B1 (en) 2013-02-20 2019-08-14 The University of Queensland Conjugate compound and uses of same
WO2014138897A1 (en) 2013-03-14 2014-09-18 Anacoti Ltd. Hyaluronic acid derivatives
US10363227B2 (en) 2013-03-27 2019-07-30 Centre Hospitalier Universitaire Vaudois Pharmaceutical formulation for use in the treatment and/or prevention of restenosis
KR102049568B1 (ko) 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
WO2014169299A1 (en) 2013-04-12 2014-10-16 Bui The Duy Temperature-release catalyst for cross-linking halyuronic acid during injection
US20160228603A1 (en) 2013-04-12 2016-08-11 Miba Medical Inc. Body augmentation device
US20150190517A1 (en) 2013-04-12 2015-07-09 Miba Medical Inc. Systems and methods for delivering cross-linked halyuronic acid into a patient
WO2014173759A1 (en) * 2013-04-22 2014-10-30 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
CA2910325A1 (en) 2013-04-25 2014-10-30 Aluron Biopharma Inc. Crosslinked hyaluronic acid compositions
US10137199B2 (en) 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
WO2014198406A1 (en) 2013-06-11 2014-12-18 Anteis S.A. Method for crosslinking hyaluronic acid; method for preparing an injectable hydrogel; hydrogel obtained; use of the obtained hydrogel
CN105451744A (zh) 2013-06-14 2016-03-30 盖尔德玛公司 包含交联的透明质酸和环糊精的组合物
WO2014206500A1 (en) 2013-06-28 2014-12-31 Galderma S.A. Method for manufacturing a shaped cross-linked hyaluronic acid product
US20160166701A1 (en) 2013-07-05 2016-06-16 Therakine Biodelivery Gmbh Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition
WO2015048408A1 (en) 2013-09-27 2015-04-02 Virginia Tech Intellectual Properties, Inc. Cross-metathesized polysaccharide derivatives and processes for preparing them
EP3054981B1 (en) 2013-10-08 2020-07-29 Ascendis Pharma A/S Protecting group comprising a purification tag
JP5734536B1 (ja) 2013-10-08 2015-06-17 キユーピー株式会社 カルボキシメチル基含有修飾ヒアルロン酸および／またはその塩の架橋物およびその製造方法
WO2015053282A1 (ja) 2013-10-08 2015-04-16 キユーピー株式会社 カルボキシメチル基含有修飾ヒアルロン酸および／またはその塩の架橋物およびその製造方法
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
KR101459070B1 (ko) 2013-12-09 2014-11-17 (주) 뉴메딕 지속성을 갖는 히알루론산 겔 조성물
JP2017503835A (ja) * 2014-01-23 2017-02-02 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 眼球疾患治療のための組成物及び方法
ES2993327T3 (en) 2014-08-06 2024-12-27 Ascendis Pharma As Prodrugs comprising an aminoalkyl glycine linker
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
DK4268843T3 (da) 2014-11-07 2025-11-10 F Hoffmann La Roche Ltd Forbedrede IL-6-antistoffer
JP2018516277A (ja) 2015-05-29 2018-06-21 アルバトロス テクノロジーズ リミテッドＡｌｂａｔｒｏｓｓ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 薬物送達用架橋ヒアルロン酸及びそれを用いた医薬製剤
EP3303365A4 (en) 2015-05-29 2019-04-24 Ascendis Pharma Inc. PRODRUGS WITH A PYROGLUTAMATE LINKER
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
KR102725051B1 (ko) 2015-09-23 2024-11-04 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들
EP3386520B1 (en) 2015-12-09 2022-07-20 The Regents of The University of California Methods of treating an ocular disease or disorder
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
CA3055985A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010626A (zh) * 2011-10-12 2014-08-27 阿森迪斯药物眼科部股份有限公司 眼病症的预防和治疗
CN104995303A (zh) * 2012-12-18 2015-10-21 诺华股份有限公司 利用结合乙酰透明质酸的肽标签的组合物和方法

Also Published As

Publication number Publication date
IL269506B1 (en) 2023-12-01
RU2019133326A (ru) 2021-04-22
US20250255973A1 (en) 2025-08-14
MA49265A (fr) 2020-02-05
ZA201905930B (en) 2024-01-31
US12246070B2 (en) 2025-03-11
JP2023058511A (ja) 2023-04-25
AU2018240375C1 (en) 2024-02-01
BR112019019658A2 (pt) 2020-04-22
AU2018240375A1 (en) 2019-09-26
CN110891611A (zh) 2020-03-17
RU2019133326A3 (enExample) 2021-10-19
AU2018240375A2 (en) 2020-03-05
IL269506B2 (en) 2024-04-01
JP7216006B2 (ja) 2023-01-31
IL269506A (en) 2019-11-28
CA3055985A1 (en) 2018-09-27
AR111190A1 (es) 2019-06-12
TW201842936A (zh) 2018-12-16
KR20200007776A (ko) 2020-01-22
WO2018175788A1 (en) 2018-09-27
KR102715397B1 (ko) 2024-10-10
US20230414770A1 (en) 2023-12-28
JP2020515545A (ja) 2020-05-28
SG10202107829YA (en) 2021-08-30
EP3600441A1 (en) 2020-02-05
KR20240150530A (ko) 2024-10-15
CN110891611B (zh) 2024-03-29
SG11201908547VA (en) 2019-10-30
US11642415B2 (en) 2023-05-09
US20200222547A1 (en) 2020-07-16
AU2018240375B2 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
TWI857935B (zh) 水凝膠交聯化的玻尿酸前藥組合物及方法
US11891437B2 (en) Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer
JP2022017288A (ja) 抗ｖｅｇｆ抗体の最適化変異体
RU2812787C2 (ru) Пролекарственные композиции на основе гидрогеля поперечно-сшитой гиалуроновой кислоты и способы
BR122022024506B1 (pt) Composições farmacêuticas compreendendo conjugados fármacoácido hialurônico e uso destas na fabricação de um medicamento para tratar uma indicação ocular
RU2782355C2 (ru) Оптимизированные композиции антител для лечения заболеваний глаз
BR112019019658B1 (pt) Conjugado de fármaco-ácido hialurônico, seu método de produção, composição farmacêutica e uso da mesma
HK40016409B (zh) 用於治疗眼部病症的优化的抗体组合物
HK1254198B (zh) 抗-vegf抗体的优化的变体